• Recruiting

NCT04564703: EMN26 Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

Updated: May 24

EMN26

NCT04564703: Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients


iberdomide maintenance

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients


This is a phase II study to evaluate the efficacy and safety of different doses of iberdomide continuous therapy as maintenance treatment after transplant.


Sponsor

European Myeloma Network


Collaborators

Celgene Corporation

Healt Data Specialists - HeaDS (CRO)

EMN Research Italy Impresa Sociale Srl


Location

Europe

 

ClinicalTrials.gov Identifier: NCT04564703


Official Title: Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients


First Posted: September 25, 2020


Click here for details on Clinicaltrials.gov


EMN26 - European Myeloma Network (myeloma-europe.org)

 

Drug: Iberdomide

 

Locations

Europe

France

Greece

Italy

Netherlands






Posts Archive